We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo ADLM 2025 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New System Breaks Technology and Cost Barriers for High-Throughput Large-Genome Sequencing

By LabMedica International staff writers
Posted on 28 Jan 2014
Image: The HiSeq X Ten, composed of 10 HiSeq X Systems, breaks the USD 1000 barrier for a 30x human genome, enabling population-scale projects on genotypic variation to understand and improve human health (Photo courtesy of Illumina).
Image: The HiSeq X Ten, composed of 10 HiSeq X Systems, breaks the USD 1000 barrier for a 30x human genome, enabling population-scale projects on genotypic variation to understand and improve human health (Photo courtesy of Illumina).
A new DNA sequencing system utilizes advanced design features to generate massive throughput and enable the world's first USD 1000 human genome sequence.

This achievement has been reached with the new HiSeq X Ten Sequencing System from Illumina (San Diego, CA, USA). The platform includes technology breakthroughs that enable researchers to undertake population and disease studies of unprecedented scale by providing the throughput to sequence tens of thousands of human whole genomes in a single year in a single lab. The HiSeq X Ten is the world’s first platform to deliver high quality, high-coverage human genome sequences for less than USD 1,000—inclusive of typical instrument depreciation, DNA extraction, library preparation, and estimated labor.

Purpose-built for population-scale human whole genome sequencing, the HiSeq X Ten is a platform especially suitable for scientists and institutions focused on the discovery of genotypic variation to enable a deeper understanding of biology and disease. It can deliver a comprehensive catalog of human variation within and outside of coding regions. “The ability to explore the human genome on this scale will bring the study of cancer and complex diseases to a new level. Breaking the ‘sound barrier’ of human genetics not only pushes us through a psychological milestone, it enables projects of unprecedented scale. We are excited to see what lies on the other side,” said Jay Flatley, CEO, Illumina.

Building on the proven performance of Illumina sequencing-by-synthesis (SBS) technology, HiSeq X Ten utilizes a number of advanced design features to generate massive throughput. Patterned flow cells (which contain billions of nanowells at fixed locations) combined with a new clustering chemistry deliver a significant increase in data density (6 billion clusters per run). Using state-of-the art optics and faster chemistry, HiSeq X Ten can process sequencing flow cells more quickly than ever before – generating a 10x increase in daily throughput when compared to current HiSeq 2500 performance. The HiSeq X Ten is sold as a set of 10 or more ultra-high throughput sequencing systems, each generating up to 1.8 terabases (Tb) of sequencing data in less than 3 days or up to 600 gigabases (Gb) per day, per system.

Initial users of the transformative HiSeq X Ten System include Macrogen (Seoul, Republic of Korea) and its CLIA laboratory (Rockville, MD, USA), the Broad Institute (Cambridge, MA, USA), and the Garvan Institute of Medical Research (Sydney, Australia).

“The sequencing capacity and economies of scale of the HiSeq X Ten facility will also allow Garvan to accelerate the introduction of clinical genomics and next-generation medicine in Australia,” said Prof. John Mattick, Executive Director of the Garvan Institute of Medical Research.

Eric Lander, founding director of the Broad Institute and professor of biology at MIT, said, “The HiSeq X Ten should give us the ability to analyze complete genomic information from huge sample populations. Over the next few years, we have an opportunity to learn as much about the genetics of human disease as we have learned in the history of medicine.”

“Macrogen will deploy this groundbreaking technology to open a new era of large-scale, whole genome sequencing in our certified CLIA laboratory,” said Dr. Jeong-Sun Seo, Chairman of Macrogen; “Additionally, we will use the HiSeq X Ten to continue our collaboration with the Genomic Medicine Institute of Seoul National University focused on sequencing Asian populations in order to build a genomics database for use in medical research and healthcare applications.”

Related Links:

Illumina


Gold Member
Veterinary Hematology Analyzer
Exigo H400
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Host Response Immunoassay Test
MeMed BV
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500

DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: Brain biomarkers of Alzheimer\'s disease can be detected as early as middle age (Photo courtesy of University of Shutterstock)

Blood-Based Biomarkers Could Detect Alzheimer's as Early as Middle Age

As the global population ages, Alzheimer's disease and other dementing diseases are becoming more prevalent. The disease processes leading to Alzheimer's symptoms can begin years or even decades before... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: Micrograph showing the distribution of misfolded proteins in myeloma cells (Photo courtesy of Helmholtz Munich)

Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels

Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow, leading to abnormal protein production, weakened immunity, and organ damage. Traditional methods for evaluating myeloma... Read more
PURITAN MEDICAL